Clinical Trials Logo

Cholesterol Lowering clinical trials

View clinical trials related to Cholesterol Lowering.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT05038436 Completed - Clinical trials for Cholesterol Lowering

Influence of Polyglucosamine L112 on Serum Surrogate Markers of Cholesterol Absorption

Start date: September 16, 2021
Phase: N/A
Study type: Interventional

Obesity is widespread and the number of overweight people has tripled from 1975 to 2016. According to the WHO (World Health Organisation), 1.9 billion adults worldwide are overweight, of which 650 million are obese. Thus, obesity is caused by a balance problem between the amount of food consumed and the energy used. The weighting of the diet in favour of a far too high fat intake also has a negative influence on the fat metabolism. Obesity is associated with a number of secondary diseases, such as diabetes mellitus, increased inflammatory parameters in the blood and a higher risk of heart attack and stroke. These secondary diseases reduce the quality and duration of life of the person affected. In animal studies, polyglucosamine was found to have a cholesterol-lowering effect. In human studies conducted over 3 and 12 months, formoline L112 was shown to lower LDL levels in the blood. For research purposes, the present study will focus on investigating whether the intake of polyglucosamine L112 leads to a reduction in cholesterol intake from food, which should result in a reduced fat and thus calorie intake.